Rapalogues for Autism Phenotype in TSC: A Feasibility Study

NCT ID: NCT01929642

Last Updated: 2021-03-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2016-08-31

Brief Summary

The purpose of this study is to assess the feasibility and safety of administering rapalogues, sirolimus or everolimus, in participants with Tuberous Sclerosis Complex (TSC) and self-injury and to measure cognitive and behavioral changes, including reduction in autistic symptoms, self-injurious and aggressive behaviors, as well as improvements in cognition across multiple domains of cognitive function.

Detailed Description

This is a feasibility and safety study primarily designed to assess the feasibility and safety of conducting a larger clinical trial with sirolimus in individuals with TSC. The present study will employ an ABA design in which three pediatric participants will be selected to receive baseline medical, developmental, behavioral, and cognitive evaluations, followed by a 26 week administration of sirolimus, repeated baseline assessments at the end of the 26 week treatment phase, and a 4 week titrated withdrawal followed by a 22 week period in which no rapalogue is administered. All participants will again be administered baseline medical, behavioral, and cognitive evaluations at the end of the study in order to compare all evaluations done at baseline, the end of the 26 week treatment, and completion of the study. These comparisons will be done to assess secondary outcomes that include reductions in autistic symptoms, self-injury, and aggression, as well as improvements in cognitive function across multiple domains. Furthermore, administration of the secondary outcome measures will also allow us to better understand the sensitivity of these measures in patients with TSC during the course of a clinical trial.

Families of potentially eligible children who express interest in the study and meet prescreening criteria will be invited to attend a screening visit to determine eligibility, inclusion/exclusion criteria, and availability for eight additional study visits. Prior to enrollment, informed consent will be obtained from the parent or legal guardian.

Investigators will use the methods of analysis of single-subject research (ABA design, where first A represents baseline, B represents treatment, and A represents reversal of treatment. The analysis will focus on each of the 3 subjects separately. Data on feasibility and safety (primary outcome) and on frequency of disruptive behavior (secondary outcome) will be plotted and visually inspected to detect any temporal changes by phase: 1. Baseline, 2. Treatment, 3. After treatment. Data in each phase will be summarized as mean +/- standard deviation (SD). We will use the summary data to assess the potential effect of the intervention. Consistency of the effect will be examined across the 3 study participants.

Conditions

Tuberous Sclerosis Complex; Self-injury; Autism

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sirolimus or Everolimus

Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)

Group Type: EXPERIMENTAL

Sirolimus

Intervention Type: DRUG

Everolimus

Intervention Type: DRUG

Interventions

Sirolimus

Intervention Type: DRUG

Everolimus

Intervention Type: DRUG

Other Intervention Names

Rapamune, Rapamycin; Afinitor

Eligibility Criteria

Inclusion Criteria

1. Diagnosed with Tuberous Sclerosis Complex as defined by the revised NIH consensus criteria

2. Possible autism or autism spectrum disorder and/or possible intellectual disability and/or global developmental delay

3. Currently displaying disruptive behaviors, such as self-injury and aggression

4. Seizures or epilepsy with at least one seizure within six months prior to enrollment

5. 2-30 years of age

6. English-speaking caregiver if participant is non-verbal.

7. If individuals are currently being treated with everolimus, they must have been taking it for less than or equal to 6 months.

Exclusion Criteria

1. Participants who require live vaccines that are contraindicated with sirolimus will be excluded - bacille Calmette Guerin(BCG), measles-mumps-rubella vaccine(MMR), poliovirus, rotavirus, smallpox, typhoid, varicella, or yellow fever.

2. Participants who have a history of multiple or severe infections, or reside in a household with anyone who has a chronic, contagious condition will be excluded. Multiple infections will be defined as eight or more lifetime episodes of otitis media or two or more lifetime episodes of bacterial pneumonia. Severe infections will be defined as infections requiring more than one hospital admission for treatment.

3. Participants with any of the following laboratory abnormalities will be excluded: hematocrit < 27%, absolute neutrophil count(ANC) < 1,500, platelet count < 100,000, serum glutamate oxaloacetate transaminase(SGOT) or serum glutamate pyruvate transaminase (SGPT) > two times normal for age, bilirubin > two times normal for age, alkaline phosphatase > two times normal for age, epidermal growth factor receptor (eGFR) < 30, or evidence of renal failure, hypercholesterolemia.

4. Participants who have medical contraindications to undergoing an MRI will be excluded.

5. Participants with devices implanted in the brain will be excluded.

6. Pregnant participants will be excluded. All young ladies of child bearing potential will have a blood test for pregnancy prior to the start of the study and every study visit for the duration of the study.

7. Participants who have a history of herpes simplex virus, cytomegalovirus, and/or HIV infection will be excluded

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tanjala Gipson, MD

Role: PRINCIPAL_INVESTIGATOR

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Locations

Kennedy Krieger Institute

Baltimore, Maryland, United States

Countries

United States

References

Napolioni V, Curatolo P. Genetics and molecular biology of tuberous sclerosis complex. Curr Genomics. 2008 Nov;9(7):475-87. doi: 10.2174/138920208786241243.

Reference Type: BACKGROUND

PMID: 19506736 (View on PubMed)

Gomez M, Sampson JR, Whittemore VH, editors. Tuberous sclerosis complex. 3rd ed. Oxford University Press; 1999.

Reference Type: BACKGROUND

Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125-7. doi: 10.1111/j.1749-6632.1991.tb37754.x. No abstract available.

Reference Type: BACKGROUND

PMID: 2039137 (View on PubMed)

Cross JH. Neurocutaneous syndromes and epilepsy-issues in diagnosis and management. Epilepsia. 2005;46 Suppl 10:17-23. doi: 10.1111/j.1528-1167.2005.00353.x.

Reference Type: BACKGROUND

PMID: 16359466 (View on PubMed)

Curatolo P, Bombardieri R, Verdecchia M, Seri S. Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment. J Child Neurol. 2005 Apr;20(4):318-25. doi: 10.1177/08830738050200040901.

Reference Type: BACKGROUND

PMID: 15921233 (View on PubMed)

Joinson C, O'Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med. 2003 Feb;33(2):335-44. doi: 10.1017/s0033291702007092.

Reference Type: BACKGROUND

PMID: 12622312 (View on PubMed)

de Vries PJ. Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics. 2010 Jul;7(3):275-82. doi: 10.1016/j.nurt.2010.05.001.

Reference Type: BACKGROUND

PMID: 20643380 (View on PubMed)

Smalley SL. Autism and tuberous sclerosis. J Autism Dev Disord. 1998 Oct;28(5):407-14. doi: 10.1023/a:1026052421693.

Reference Type: BACKGROUND

PMID: 9813776 (View on PubMed)

Bolton PF, Park RJ, Higgins JN, Griffiths PD, Pickles A. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain. 2002 Jun;125(Pt 6):1247-55. doi: 10.1093/brain/awf124.

Reference Type: BACKGROUND

PMID: 12023313 (View on PubMed)

Prescibing Information for Sirolimus. 1999).

Reference Type: BACKGROUND

Sindhi R. Sirolimus in pediatric transplant recipients. Transplant Proc. 2003 May;35(3 Suppl):113S-114S. doi: 10.1016/s0041-1345(03)00223-9.

Reference Type: BACKGROUND

PMID: 12742479 (View on PubMed)

Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008 Aug;14(8):843-8. doi: 10.1038/nm1788. Epub 2008 Jun 22.

Reference Type: BACKGROUND

PMID: 18568033 (View on PubMed)

Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008 Apr;63(4):444-53. doi: 10.1002/ana.21331.

Reference Type: BACKGROUND

PMID: 18389497 (View on PubMed)

Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006 Mar;59(3):490-8. doi: 10.1002/ana.20784.

Reference Type: BACKGROUND

PMID: 16453317 (View on PubMed)

Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11. doi: 10.1056/NEJMoa1001671.

Reference Type: BACKGROUND

PMID: 21047224 (View on PubMed)

Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011 Jun 15;17(12):4071-81. doi: 10.1158/1078-0432.CCR-11-0445. Epub 2011 Apr 27.

Reference Type: BACKGROUND

PMID: 21525172 (View on PubMed)

Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008 May 21;28(21):5422-32. doi: 10.1523/JNEUROSCI.0955-08.2008.

Reference Type: BACKGROUND

PMID: 18495876 (View on PubMed)

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011 Apr 28;364(17):1595-606. doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16.

Reference Type: BACKGROUND

PMID: 21410393 (View on PubMed)

Flaig TW, Costa LJ, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ, Drabkin H. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer. 2010 Sep 7;103(6):796-801. doi: 10.1038/sj.bjc.6605868.

Reference Type: BACKGROUND

PMID: 20823888 (View on PubMed)

Asrani SK, Leise MD, West CP, Murad MH, Pedersen RA, Erwin PJ, Tian J, Wiesner RH, Kim WR. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology. 2010 Oct;52(4):1360-70. doi: 10.1002/hep.23835.

Reference Type: BACKGROUND

PMID: 20815021 (View on PubMed)

Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1;16(11):3057-66. doi: 10.1158/1078-0432.CCR-10-0124. Epub 2010 May 25.

Reference Type: BACKGROUND

PMID: 20501622 (View on PubMed)

Habib SL. Tuberous sclerosis complex and DNA repair. Adv Exp Med Biol. 2010;685:84-94. doi: 10.1007/978-1-4419-6448-9_8.

Reference Type: BACKGROUND

PMID: 20687497 (View on PubMed)

Rapamune: U.S. Physician Prescribing Information. 1999).

Reference Type: BACKGROUND

Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant. 2008 Dec;13(6):563-8. doi: 10.1097/MOT.0b013e3283186ba9.

Reference Type: BACKGROUND

PMID: 19060543 (View on PubMed)

Novak M, Guest C. Application of a multidimensional caregiver burden inventory. Gerontologist. 1989 Dec;29(6):798-803. doi: 10.1093/geront/29.6.798.

Reference Type: BACKGROUND

PMID: 2516000 (View on PubMed)

Abidin R. Parental stress index - 4, short form. fourth edition ed. Odessa, FL: Psychological Assessment Resources, Inc.; 2009.

Reference Type: BACKGROUND

Staley BA, Montenegro MA, Major P, Muzykewicz DA, Halpern EF, Kopp CM, Newberry P, Thiele EA. Self-injurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients. Epilepsy Behav. 2008 Nov;13(4):650-3. doi: 10.1016/j.yebeh.2008.07.010. Epub 2008 Aug 30.

Reference Type: BACKGROUND

PMID: 18703161 (View on PubMed)

Seizuretracker.com [Internet].; 2012.

Reference Type: BACKGROUND

Roach ES, DiMario FJ, Kandt RS, Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol. 1999 Jun;14(6):401-7. doi: 10.1177/088307389901400610.

Reference Type: BACKGROUND

PMID: 10385849 (View on PubMed)

O'Callaghan FJ, Harris T, Joinson C, Bolton P, Noakes M, Presdee D, Renowden S, Shiell A, Martyn CN, Osborne JP. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child. 2004 Jun;89(6):530-3. doi: 10.1136/adc.2003.026815.

Reference Type: BACKGROUND

PMID: 15155396 (View on PubMed)

Asano E, Chugani DC, Muzik O, Behen M, Janisse J, Rothermel R, Mangner TJ, Chakraborty PK, Chugani HT. Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction. Neurology. 2001 Oct 9;57(7):1269-77. doi: 10.1212/wnl.57.7.1269.

Reference Type: BACKGROUND

PMID: 11591847 (View on PubMed)

Doherty C, Goh S, Young Poussaint T, Erdag N, Thiele EA. Prognostic significance of tuber count and location in tuberous sclerosis complex. J Child Neurol. 2005 Oct;20(10):837-41. doi: 10.1177/08830738050200101301.

Reference Type: BACKGROUND

PMID: 16417883 (View on PubMed)

Raznahan A, Higgins NP, Griffiths PD, Humphrey A, Yates JR, Bolton PF. Biological markers of intellectual disability in tuberous sclerosis. Psychol Med. 2007 Sep;37(9):1293-304. doi: 10.1017/S0033291707000177. Epub 2007 Mar 5.

Reference Type: BACKGROUND

PMID: 17335641 (View on PubMed)

Roid G, Miller L. Leiter international performance scale, revised. Torrance, CA: Western Psychological Services; 1998.

Reference Type: BACKGROUND

Mullen E. Mullen scales of early learning. Circle Pines, MN: American Guidance Service, Inc.; 1995.

Reference Type: BACKGROUND

Wachtel RC, Shapiro BK, Palmer FB, Allen MC, Capute AJ. CAT/CLAMS. A tool for the pediatric evaluation of infants and young children with developmental delay. Clinical Adaptive Test/Clinical Linguistic and Auditory Milestone Scale. Clin Pediatr (Phila). 1994 Jul;33(7):410-5. doi: 10.1177/000992289403300706.

Reference Type: BACKGROUND

PMID: 7525138 (View on PubMed)

Iwata BA, Pace GM, Kissel RC, Nau PA, Farber JM. The Self-Injury Trauma (SIT) Scale: a method for quantifying surface tissue damage caused by self-injurious behavior. J Appl Behav Anal. 1990 Spring;23(1):99-110. doi: 10.1901/jaba.1990.23-99.

Reference Type: BACKGROUND

PMID: 2335488 (View on PubMed)

Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000 Jun;30(3):205-23.

Reference Type: BACKGROUND

PMID: 11055457 (View on PubMed)

Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994 Oct;24(5):659-85. doi: 10.1007/BF02172145.

Reference Type: BACKGROUND

PMID: 7814313 (View on PubMed)

Constantino J. The social responsiveness scale. Los Angeles: Western Psychological Services; 2002.

Reference Type: BACKGROUND

Rutter M, Bailey A, Lord C. Social communication questionnaire. Western Psychological Services; 2003.

Reference Type: BACKGROUND

Granader YE, Bender HA, Zemon V, Rathi S, Nass R, Macallister WS. The clinical utility of the Social Responsiveness Scale and Social Communication Questionnaire in tuberous sclerosis complex. Epilepsy Behav. 2010 Jul;18(3):262-6. doi: 10.1016/j.yebeh.2010.04.010.

Reference Type: BACKGROUND

PMID: 20554253 (View on PubMed)

Mirenda P, Smith IM, Vaillancourt T, Georgiades S, Duku E, Szatmari P, Bryson S, Fombonne E, Roberts W, Volden J, Waddell C, Zwaigenbaum L; Pathways in ASD Study Team. Validating the Repetitive Behavior Scale-revised in young children with autism spectrum disorder. J Autism Dev Disord. 2010 Dec;40(12):1521-30. doi: 10.1007/s10803-010-1012-0.

Reference Type: BACKGROUND

PMID: 20405194 (View on PubMed)

Kazdin AE. Single-case research designs in clinical child psychiatry. J Am Acad Child Psychiatry. 1983 Sep;22(5):423-32. doi: 10.1016/s0002-7138(09)61503-x. No abstract available.

Reference Type: BACKGROUND

PMID: 6630801 (View on PubMed)

Sanchez CP, He YZ. Bone growth during rapamycin therapy in young rats. BMC Pediatr. 2009 Jan 13;9:3. doi: 10.1186/1471-2431-9-3.

Reference Type: BACKGROUND

PMID: 19144108 (View on PubMed)

Alvarez-Garcia O, Carbajo-Perez E, Garcia E, Gil H, Molinos I, Rodriguez J, Ordonez FA, Santos F. Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol. 2007 Jul;22(7):954-61. doi: 10.1007/s00467-007-0456-8. Epub 2007 Mar 17.

Reference Type: BACKGROUND

PMID: 17370095 (View on PubMed)

Rangel GA, Ariceta G. Growth failure associated with sirolimus: case report. Pediatr Nephrol. 2009 Oct;24(10):2047-50. doi: 10.1007/s00467-009-1215-9. Epub 2009 Jun 3.

Reference Type: BACKGROUND

PMID: 19495804 (View on PubMed)

Related Links

http://www.kennedykrieger.org/research-training/participate-in-research/clinical-trials

Kennedy Krieger Institute Clinical Trials Unit

http://www.kennedykrieger.org/patient-care/patient-care-programs/outpatient-programs/tuberous-sclerosis-clinic

TSC clinic at Kennedy Krieger Institute

Other Identifiers

AM00037881

Identifier Type: -

Identifier Source: org_study_id